Are you Dr. Taylor?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 48 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4805 NE Glisan St Ste 11n
Portland, OR 97213Phone+1 503-215-1350- Is this information wrong?
Summary
- Dr. Matthew Taylor, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon and Washington. He is affiliated with Providence Portland Medical Center, OHSU Hospital, and Portland HCS.
Education & Training
Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 2007 - 2011
University of WashingtonResidency, Internal Medicine, 2005 - 2007
Oregon Health and Science University School of MedicineClass of 2005
Certifications & Licensure
OR State Medical License 2007 - 2025
WA State Medical License 2005 - 2007- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Start of enrollment: 2010 May 01
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEvaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.Makker, V., Taylor, M., Aghajanian, C., Cohn, A., Brose, M., Simone, C., Cao, Z., Suttner, L., Loboda, A., Cristescu, R., Jelinic, P., Orlowski, R., Dutta, L., Matsui,...> ;Journal for Immunotherapy of Cancer. 2024 Jan 19
- 7 citationsIndividualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber, J., Carlino, M., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M., Kim, K., McKean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Pecora, A., Sh...> ;Lancet. 2024 Feb 17
- Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Viola W Zhu, Julien Hadoux, Giuseppe Curigliano, Lori Wirth, Justin F Gainor, Guzman Alo...> ;Thyroid. 2024 Jan 1
- Join now to see all
Press Mentions
RET-Targeted Therapy Success in Thyroid CancersAugust 20th, 2019
Parents' Concerns over HPV Vaccine Are ValidApril 9th, 2018- 'Anal Cancer Not Unusual in Ja'April 8th, 2018
- Join now to see all
Hospital Affiliations
Portland HCSPortland, Oregon
OHSU HospitalPortland, Oregon
Providence Portland Medical CenterPortland, Oregon
